190 related articles for article (PubMed ID: 11911852)
1. Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1.
Idris I; Patiag D; Gray S; Donnelly R
Biochem Pharmacol; 2002 Mar; 63(5):993-6. PubMed ID: 11911852
[TBL] [Abstract][Full Text] [Related]
2. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Parkes DG; Pittner R; Jodka C; Smith P; Young A
Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
[TBL] [Abstract][Full Text] [Related]
3. Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats.
Sancho V; Trigo MV; González N; Valverde I; Malaisse WJ; Villanueva-Peñacarrillo ML
J Mol Endocrinol; 2005 Aug; 35(1):27-38. PubMed ID: 16087719
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes.
Luque MA; González N; Márquez L; Acitores A; Redondo A; Morales M; Valverde I; Villanueva-Peñacarrillo ML
J Endocrinol; 2002 Jun; 173(3):465-73. PubMed ID: 12065236
[TBL] [Abstract][Full Text] [Related]
5. Effect of GLP-1 on glucose transport and its cell signalling in human myocytes.
González N; Acitores A; Sancho V; Valverde I; Villanueva-Peñacarrillo ML
Regul Pept; 2005 Mar; 126(3):203-11. PubMed ID: 15664668
[TBL] [Abstract][Full Text] [Related]
6. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
Kolligs F; Fehmann HC; Göke R; Göke B
Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
[TBL] [Abstract][Full Text] [Related]
7. Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes.
Wang L; Guo F; Wei S; Zhao R
Peptides; 2011 Jun; 32(6):1313-9. PubMed ID: 21453734
[TBL] [Abstract][Full Text] [Related]
8. Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways.
MacDonald PE; Wang X; Xia F; El-kholy W; Targonsky ED; Tsushima RG; Wheeler MB
J Biol Chem; 2003 Dec; 278(52):52446-53. PubMed ID: 14565957
[TBL] [Abstract][Full Text] [Related]
9. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
Perry T; Lahiri DK; Chen D; Zhou J; Shaw KT; Egan JM; Greig NH
J Pharmacol Exp Ther; 2002 Mar; 300(3):958-66. PubMed ID: 11861804
[TBL] [Abstract][Full Text] [Related]
10. Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle.
Acitores A; González N; Sancho V; Valverde I; Villanueva-Peñacarrillo ML
J Endocrinol; 2004 Mar; 180(3):389-98. PubMed ID: 15012593
[TBL] [Abstract][Full Text] [Related]
11. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle.
Alcántara AI; Morales M; Delgado E; López-Delgado MI; Clemente F; Luque MA; Malaisse WJ; Valverde I; Villanueva-Peñacarrillo ML
Arch Biochem Biophys; 1997 May; 341(1):1-7. PubMed ID: 9143346
[TBL] [Abstract][Full Text] [Related]
12. Incretin hormones and insulin sensitivity.
Hansen PA; Corbett JA
Trends Endocrinol Metab; 2005; 16(4):135-6. PubMed ID: 15860408
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.
Tourrel C; Bailbé D; Meile MJ; Kergoat M; Portha B
Diabetes; 2001 Jul; 50(7):1562-70. PubMed ID: 11423477
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle.
Arnés L; González N; Tornero-Esteban P; Sancho V; Acitores A; Valverde I; Delgado E; Villanueva-Peñacarrillo ML
Int J Mol Med; 2008 Jul; 22(1):127-32. PubMed ID: 18575785
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.
Ebinger M; Jehle DR; Fussgaenger RD; Fehmann HC; Jehle PM
Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E88-94. PubMed ID: 10893327
[TBL] [Abstract][Full Text] [Related]
16. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor.
Yang H; Egan JM; Wang Y; Moyes CD; Roth J; Montrose MH; Montrose-Rafizadeh C
Am J Physiol; 1998 Sep; 275(3):C675-83. PubMed ID: 9730951
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 and islet lipolysis.
Sörhede Winzell M; Ahrén B
Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells.
Zhou J; Wang X; Pineyro MA; Egan JM
Diabetes; 1999 Dec; 48(12):2358-66. PubMed ID: 10580424
[TBL] [Abstract][Full Text] [Related]
19. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.
Tourrel C; Bailbe D; Lacorne M; Meile MJ; Kergoat M; Portha B
Diabetes; 2002 May; 51(5):1443-52. PubMed ID: 11978641
[TBL] [Abstract][Full Text] [Related]
20. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
